Anavex Life Sciences Corp. (NASDAQ:AVXL) Stake Lifted by Opus Capital Group LLC

Opus Capital Group LLC increased its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 6.1% in the 4th quarter, HoldingsChannel reports. The fund owned 34,700 shares of the biotechnology company’s stock after acquiring an additional 2,000 shares during the period. Opus Capital Group LLC’s holdings in Anavex Life Sciences were worth $373,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. JPMorgan Chase & Co. boosted its holdings in Anavex Life Sciences by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 42,565 shares of the biotechnology company’s stock worth $242,000 after buying an additional 1,191 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Anavex Life Sciences by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,980 shares of the biotechnology company’s stock worth $193,000 after buying an additional 1,671 shares in the last quarter. Foster Victor Wealth Advisors LLC boosted its holdings in Anavex Life Sciences by 5.6% during the fourth quarter. Foster Victor Wealth Advisors LLC now owns 37,663 shares of the biotechnology company’s stock worth $405,000 after buying an additional 2,000 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Anavex Life Sciences by 8.5% during the second quarter. The Manufacturers Life Insurance Company now owns 30,510 shares of the biotechnology company’s stock worth $129,000 after buying an additional 2,401 shares in the last quarter. Finally, Carnegie Investment Counsel boosted its holdings in Anavex Life Sciences by 4.7% during the fourth quarter. Carnegie Investment Counsel now owns 76,778 shares of the biotechnology company’s stock worth $825,000 after buying an additional 3,445 shares in the last quarter. 31.55% of the stock is currently owned by institutional investors.

Anavex Life Sciences Stock Performance

Shares of NASDAQ:AVXL opened at $8.52 on Monday. The company has a market cap of $722.67 million, a PE ratio of -16.38 and a beta of 0.69. Anavex Life Sciences Corp. has a 52 week low of $3.25 and a 52 week high of $14.44. The firm has a 50 day simple moving average of $9.94 and a 200 day simple moving average of $7.73.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03. On average, equities analysts predict that Anavex Life Sciences Corp. will post -0.73 earnings per share for the current year.

Analysts Set New Price Targets

AVXL has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and set a $42.00 target price on shares of Anavex Life Sciences in a report on Tuesday, January 28th. D. Boral Capital restated a “buy” rating and set a $46.00 target price on shares of Anavex Life Sciences in a report on Wednesday, February 12th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.